img

Global Short-acting Recombinant Human Erythropoietin Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Short-acting Recombinant Human Erythropoietin Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood.
Global Short-acting Recombinant Human Erythropoietin market is projected to reach US$ 13830 million in 2029, increasing from US$ 9168 million in 2022, with the CAGR of 6.2% during the period of 2024 to 2029. Demand from Anemia and Kidney Disorders are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Short-acting Recombinant Human Erythropoietin industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Short-acting Recombinant Human Erythropoietin key manufacturers include Amgen, Johnson & Johnson, Roche, Kyowa Kirin, LG Chem, Daewoong Pharmaceutical, Wockhardt, CJ Healthcare and 3SBio, etc. Amgen, Johnson & Johnson, Roche are top 3 players and held % sales share in total in 2022.
Short-acting Recombinant Human Erythropoietin can be divided into Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Others, etc. Epoetin-alfa is the mainstream product in the market, accounting for % sales share globally in 2022.
Short-acting Recombinant Human Erythropoietin is widely used in various fields, such as Anemia, Kidney Disorders and Others,, etc. Anemia provides greatest supports to the Short-acting Recombinant Human Erythropoietin industry development. In 2022, global % sales of Short-acting Recombinant Human Erythropoietin went into Anemia filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Short-acting Recombinant Human Erythropoietin market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Amgen
Johnson & Johnson
Roche
Kyowa Kirin
LG Chem
Daewoong Pharmaceutical
Wockhardt
CJ Healthcare
3SBio
Kexing Biopharm
Harbin Pharmaceutical Group
Beijing Four Rings Bio-Pharmaceutical
Segment by Type
Epoetin-alfa
Epoetin-beta
Darbepoetin-alfa
Others

Segment by Application


Anemia
Kidney Disorders
Others

Segment by Region


North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Short-acting Recombinant Human Erythropoietin market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Short-acting Recombinant Human Erythropoietin, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Short-acting Recombinant Human Erythropoietin industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Short-acting Recombinant Human Erythropoietin in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Short-acting Recombinant Human Erythropoietin introduction, etc. Short-acting Recombinant Human Erythropoietin Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Short-acting Recombinant Human Erythropoietin market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.

Table of Content

1 Short-acting Recombinant Human Erythropoietin Market Overview
1.1 Short-acting Recombinant Human Erythropoietin Product Overview
1.2 Short-acting Recombinant Human Erythropoietin Market Segment by Type
1.2.1 Epoetin-alfa
1.2.2 Epoetin-beta
1.2.3 Darbepoetin-alfa
1.2.4 Others
1.3 Global Short-acting Recombinant Human Erythropoietin Market Size by Type
1.3.1 Global Short-acting Recombinant Human Erythropoietin Market Size Overview by Type (2018-2029)
1.3.2 Global Short-acting Recombinant Human Erythropoietin Historic Market Size Review by Type (2018-2024)
1.3.3 Global Short-acting Recombinant Human Erythropoietin Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Short-acting Recombinant Human Erythropoietin Sales Breakdown by Type (2018-2024)
1.4.2 Europe Short-acting Recombinant Human Erythropoietin Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific Short-acting Recombinant Human Erythropoietin Sales Breakdown by Type (2018-2024)
1.4.4 Latin America Short-acting Recombinant Human Erythropoietin Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa Short-acting Recombinant Human Erythropoietin Sales Breakdown by Type (2018-2024)
2 Global Short-acting Recombinant Human Erythropoietin Market Competition by Company
2.1 Global Top Players by Short-acting Recombinant Human Erythropoietin Sales (2018-2024)
2.2 Global Top Players by Short-acting Recombinant Human Erythropoietin Revenue (2018-2024)
2.3 Global Top Players by Short-acting Recombinant Human Erythropoietin Price (2018-2024)
2.4 Global Top Manufacturers Short-acting Recombinant Human Erythropoietin Manufacturing Base Distribution, Sales Area, Product Type
2.5 Short-acting Recombinant Human Erythropoietin Market Competitive Situation and Trends
2.5.1 Short-acting Recombinant Human Erythropoietin Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Short-acting Recombinant Human Erythropoietin Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Short-acting Recombinant Human Erythropoietin as of 2022)
2.7 Date of Key Manufacturers Enter into Short-acting Recombinant Human Erythropoietin Market
2.8 Key Manufacturers Short-acting Recombinant Human Erythropoietin Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Short-acting Recombinant Human Erythropoietin Status and Outlook by Region
3.1 Global Short-acting Recombinant Human Erythropoietin Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Short-acting Recombinant Human Erythropoietin Historic Market Size by Region
3.2.1 Global Short-acting Recombinant Human Erythropoietin Sales in Volume by Region (2018-2024)
3.2.2 Global Short-acting Recombinant Human Erythropoietin Sales in Value by Region (2018-2024)
3.2.3 Global Short-acting Recombinant Human Erythropoietin Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Short-acting Recombinant Human Erythropoietin Forecasted Market Size by Region
3.3.1 Global Short-acting Recombinant Human Erythropoietin Sales in Volume by Region (2024-2029)
3.3.2 Global Short-acting Recombinant Human Erythropoietin Sales in Value by Region (2024-2029)
3.3.3 Global Short-acting Recombinant Human Erythropoietin Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Short-acting Recombinant Human Erythropoietin by Application
4.1 Short-acting Recombinant Human Erythropoietin Market Segment by Application
4.1.1 Anemia
4.1.2 Kidney Disorders
4.1.3 Others
4.2 Global Short-acting Recombinant Human Erythropoietin Market Size by Application
4.2.1 Global Short-acting Recombinant Human Erythropoietin Market Size Overview by Application (2018-2029)
4.2.2 Global Short-acting Recombinant Human Erythropoietin Historic Market Size Review by Application (2018-2024)
4.2.3 Global Short-acting Recombinant Human Erythropoietin Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Short-acting Recombinant Human Erythropoietin Sales Breakdown by Application (2018-2024)
4.3.2 Europe Short-acting Recombinant Human Erythropoietin Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Short-acting Recombinant Human Erythropoietin Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Short-acting Recombinant Human Erythropoietin Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Short-acting Recombinant Human Erythropoietin Sales Breakdown by Application (2018-2024)
5 North America Short-acting Recombinant Human Erythropoietin by Country
5.1 North America Short-acting Recombinant Human Erythropoietin Historic Market Size by Country
5.1.1 North America Short-acting Recombinant Human Erythropoietin Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Short-acting Recombinant Human Erythropoietin Sales in Volume by Country (2018-2024)
5.1.3 North America Short-acting Recombinant Human Erythropoietin Sales in Value by Country (2018-2024)
5.2 North America Short-acting Recombinant Human Erythropoietin Forecasted Market Size by Country
5.2.1 North America Short-acting Recombinant Human Erythropoietin Sales in Volume by Country (2024-2029)
5.2.2 North America Short-acting Recombinant Human Erythropoietin Sales in Value by Country (2024-2029)
6 Europe Short-acting Recombinant Human Erythropoietin by Country
6.1 Europe Short-acting Recombinant Human Erythropoietin Historic Market Size by Country
6.1.1 Europe Short-acting Recombinant Human Erythropoietin Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Short-acting Recombinant Human Erythropoietin Sales in Volume by Country (2018-2024)
6.1.3 Europe Short-acting Recombinant Human Erythropoietin Sales in Value by Country (2018-2024)
6.2 Europe Short-acting Recombinant Human Erythropoietin Forecasted Market Size by Country
6.2.1 Europe Short-acting Recombinant Human Erythropoietin Sales in Volume by Country (2024-2029)
6.2.2 Europe Short-acting Recombinant Human Erythropoietin Sales in Value by Country (2024-2029)
7 Asia-Pacific Short-acting Recombinant Human Erythropoietin by Region
7.1 Asia-Pacific Short-acting Recombinant Human Erythropoietin Historic Market Size by Region
7.1.1 Asia-Pacific Short-acting Recombinant Human Erythropoietin Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Short-acting Recombinant Human Erythropoietin Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Short-acting Recombinant Human Erythropoietin Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Short-acting Recombinant Human Erythropoietin Forecasted Market Size by Region
7.2.1 Asia-Pacific Short-acting Recombinant Human Erythropoietin Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Short-acting Recombinant Human Erythropoietin Sales in Value by Region (2024-2029)
8 Latin America Short-acting Recombinant Human Erythropoietin by Country
8.1 Latin America Short-acting Recombinant Human Erythropoietin Historic Market Size by Country
8.1.1 Latin America Short-acting Recombinant Human Erythropoietin Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Short-acting Recombinant Human Erythropoietin Sales in Volume by Country (2018-2024)
8.1.3 Latin America Short-acting Recombinant Human Erythropoietin Sales in Value by Country (2018-2024)
8.2 Latin America Short-acting Recombinant Human Erythropoietin Forecasted Market Size by Country
8.2.1 Latin America Short-acting Recombinant Human Erythropoietin Sales in Volume by Country (2024-2029)
8.2.2 Latin America Short-acting Recombinant Human Erythropoietin Sales in Value by Country (2024-2029)
9 Middle East and Africa Short-acting Recombinant Human Erythropoietin by Country
9.1 Middle East and Africa Short-acting Recombinant Human Erythropoietin Historic Market Size by Country
9.1.1 Middle East and Africa Short-acting Recombinant Human Erythropoietin Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Short-acting Recombinant Human Erythropoietin Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Short-acting Recombinant Human Erythropoietin Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Short-acting Recombinant Human Erythropoietin Forecasted Market Size by Country
9.2.1 Middle East and Africa Short-acting Recombinant Human Erythropoietin Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Short-acting Recombinant Human Erythropoietin Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Amgen
10.1.1 Amgen Company Information
10.1.2 Amgen Introduction and Business Overview
10.1.3 Amgen Short-acting Recombinant Human Erythropoietin Sales, Revenue and Gross Margin (2018-2024)
10.1.4 Amgen Short-acting Recombinant Human Erythropoietin Products Offered
10.1.5 Amgen Recent Development
10.2 Johnson & Johnson
10.2.1 Johnson & Johnson Company Information
10.2.2 Johnson & Johnson Introduction and Business Overview
10.2.3 Johnson & Johnson Short-acting Recombinant Human Erythropoietin Sales, Revenue and Gross Margin (2018-2024)
10.2.4 Johnson & Johnson Short-acting Recombinant Human Erythropoietin Products Offered
10.2.5 Johnson & Johnson Recent Development
10.3 Roche
10.3.1 Roche Company Information
10.3.2 Roche Introduction and Business Overview
10.3.3 Roche Short-acting Recombinant Human Erythropoietin Sales, Revenue and Gross Margin (2018-2024)
10.3.4 Roche Short-acting Recombinant Human Erythropoietin Products Offered
10.3.5 Roche Recent Development
10.4 Kyowa Kirin
10.4.1 Kyowa Kirin Company Information
10.4.2 Kyowa Kirin Introduction and Business Overview
10.4.3 Kyowa Kirin Short-acting Recombinant Human Erythropoietin Sales, Revenue and Gross Margin (2018-2024)
10.4.4 Kyowa Kirin Short-acting Recombinant Human Erythropoietin Products Offered
10.4.5 Kyowa Kirin Recent Development
10.5 LG Chem
10.5.1 LG Chem Company Information
10.5.2 LG Chem Introduction and Business Overview
10.5.3 LG Chem Short-acting Recombinant Human Erythropoietin Sales, Revenue and Gross Margin (2018-2024)
10.5.4 LG Chem Short-acting Recombinant Human Erythropoietin Products Offered
10.5.5 LG Chem Recent Development
10.6 Daewoong Pharmaceutical
10.6.1 Daewoong Pharmaceutical Company Information
10.6.2 Daewoong Pharmaceutical Introduction and Business Overview
10.6.3 Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Sales, Revenue and Gross Margin (2018-2024)
10.6.4 Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Products Offered
10.6.5 Daewoong Pharmaceutical Recent Development
10.7 Wockhardt
10.7.1 Wockhardt Company Information
10.7.2 Wockhardt Introduction and Business Overview
10.7.3 Wockhardt Short-acting Recombinant Human Erythropoietin Sales, Revenue and Gross Margin (2018-2024)
10.7.4 Wockhardt Short-acting Recombinant Human Erythropoietin Products Offered
10.7.5 Wockhardt Recent Development
10.8 CJ Healthcare
10.8.1 CJ Healthcare Company Information
10.8.2 CJ Healthcare Introduction and Business Overview
10.8.3 CJ Healthcare Short-acting Recombinant Human Erythropoietin Sales, Revenue and Gross Margin (2018-2024)
10.8.4 CJ Healthcare Short-acting Recombinant Human Erythropoietin Products Offered
10.8.5 CJ Healthcare Recent Development
10.9 3SBio
10.9.1 3SBio Company Information
10.9.2 3SBio Introduction and Business Overview
10.9.3 3SBio Short-acting Recombinant Human Erythropoietin Sales, Revenue and Gross Margin (2018-2024)
10.9.4 3SBio Short-acting Recombinant Human Erythropoietin Products Offered
10.9.5 3SBio Recent Development
10.10 Kexing Biopharm
10.10.1 Kexing Biopharm Company Information
10.10.2 Kexing Biopharm Introduction and Business Overview
10.10.3 Kexing Biopharm Short-acting Recombinant Human Erythropoietin Sales, Revenue and Gross Margin (2018-2024)
10.10.4 Kexing Biopharm Short-acting Recombinant Human Erythropoietin Products Offered
10.10.5 Kexing Biopharm Recent Development
10.11 Harbin Pharmaceutical Group
10.11.1 Harbin Pharmaceutical Group Company Information
10.11.2 Harbin Pharmaceutical Group Introduction and Business Overview
10.11.3 Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Sales, Revenue and Gross Margin (2018-2024)
10.11.4 Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Products Offered
10.11.5 Harbin Pharmaceutical Group Recent Development
10.12 Beijing Four Rings Bio-Pharmaceutical
10.12.1 Beijing Four Rings Bio-Pharmaceutical Company Information
10.12.2 Beijing Four Rings Bio-Pharmaceutical Introduction and Business Overview
10.12.3 Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Sales, Revenue and Gross Margin (2018-2024)
10.12.4 Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Products Offered
10.12.5 Beijing Four Rings Bio-Pharmaceutical Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Short-acting Recombinant Human Erythropoietin Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Short-acting Recombinant Human Erythropoietin Industrial Chain Analysis
11.4 Short-acting Recombinant Human Erythropoietin Market Dynamics
11.4.1 Short-acting Recombinant Human Erythropoietin Industry Trends
11.4.2 Short-acting Recombinant Human Erythropoietin Market Drivers
11.4.3 Short-acting Recombinant Human Erythropoietin Market Challenges
11.4.4 Short-acting Recombinant Human Erythropoietin Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Short-acting Recombinant Human Erythropoietin Distributors
12.3 Short-acting Recombinant Human Erythropoietin Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of Epoetin-alfa
Table 2. Major Company of Epoetin-beta
Table 3. Major Company of Darbepoetin-alfa
Table 4. Major Company of Others
Table 5. Global Short-acting Recombinant Human Erythropoietin Sales by Type 2018 VS 2022 VS 2029 (US$ Million)
Table 6. Global Short-acting Recombinant Human Erythropoietin Sales by Type (2018-2024) & (K Units)
Table 7. Global Short-acting Recombinant Human Erythropoietin Sales Market Share in Volume by Type (2018-2024)
Table 8. Global Short-acting Recombinant Human Erythropoietin Sales by Type (2018-2024) & (US& Million)
Table 9. Global Short-acting Recombinant Human Erythropoietin Market Share in Value by Type (2018-2024)
Table 10. Global Short-acting Recombinant Human Erythropoietin Price by Type (2018-2024) & (US$/Unit)
Table 11. Global Short-acting Recombinant Human Erythropoietin Sales by Type (2024-2029) & (K Units)
Table 12. Global Short-acting Recombinant Human Erythropoietin Sales Market Share in Volume by Type (2024-2029)
Table 13. Global Short-acting Recombinant Human Erythropoietin Sales by Type (2024-2029) & (US$ Million)
Table 14. Global Short-acting Recombinant Human Erythropoietin Sales Market Share in Value by Type (2024-2029)
Table 15. Global Short-acting Recombinant Human Erythropoietin Price by Type (2024-2029) & (US$/Unit)
Table 16. North America Short-acting Recombinant Human Erythropoietin Sales by Type (2018-2024) & (K Units)
Table 17. North America Short-acting Recombinant Human Erythropoietin Sales by Type (2018-2024) & (US$ Million)
Table 18. Europe Short-acting Recombinant Human Erythropoietin Sales (K Units) by Type (2018-2024)
Table 19. Europe Short-acting Recombinant Human Erythropoietin Sales by Type (2018-2024) & (US$ Million)
Table 20. Asia-Pacific Short-acting Recombinant Human Erythropoietin Sales (K Units) by Type (2018-2024)
Table 21. Asia-Pacific Short-acting Recombinant Human Erythropoietin Sales by Type (2018-2024) & (US$ Million)
Table 22. Latin America Short-acting Recombinant Human Erythropoietin Sales (K Units) by Type (2018-2024)
Table 23. Latin America Short-acting Recombinant Human Erythropoietin Sales by Type (2018-2024) & (US$ Million)
Table 24. Middle East and Africa Short-acting Recombinant Human Erythropoietin Sales (K Units) by Type (2018-2024)
Table 25. Middle East and Africa Short-acting Recombinant Human Erythropoietin Sales by Type (2018-2024) & (US$ Million)
Table 26. Global Short-acting Recombinant Human Erythropoietin Sales by Company (2018-2024) & (K Units)
Table 27. Global Short-acting Recombinant Human Erythropoietin Sales Share by Company (2018-2024)
Table 28. Global Short-acting Recombinant Human Erythropoietin Revenue by Company (2018-2024) & (US$ Million)
Table 29. Global Short-acting Recombinant Human Erythropoietin Revenue Share by Company (2018-2024)
Table 30. Global Market Short-acting Recombinant Human Erythropoietin Price by Company (2018-2024) & (US$/Unit)
Table 31. Global Short-acting Recombinant Human Erythropoietin Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 32. Global Short-acting Recombinant Human Erythropoietin Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 33. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Short-acting Recombinant Human Erythropoietin as of 2022)
Table 34. Date of Key Manufacturers Enter into Short-acting Recombinant Human Erythropoietin Market
Table 35. Key Manufacturers Short-acting Recombinant Human Erythropoietin Product Type
Table 36. Mergers & Acquisitions, Expansion Plans
Table 37. Global Short-acting Recombinant Human Erythropoietin Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2029
Table 38. Global Short-acting Recombinant Human Erythropoietin Sales by Region (2018-2024) & (K Units)
Table 39. Global Short-acting Recombinant Human Erythropoietin Sales Market Share in Volume by Region (2018-2024)
Table 40. Global Short-acting Recombinant Human Erythropoietin Sales by Region (2018-2024) & (US$ Million)
Table 41. Global Short-acting Recombinant Human Erythropoietin Sales Market Share in Value by Region (2018-2024)
Table 42. Global Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 43. Global Short-acting Recombinant Human Erythropoietin Sales by Region (2024-2029) & (K Units)
Table 44. Global Short-acting Recombinant Human Erythropoietin Sales Market Share in Volume by Region (2024-2029)
Table 45. Global Short-acting Recombinant Human Erythropoietin Sales by Region (2024-2029) & (US$ Million)
Table 46. Global Short-acting Recombinant Human Erythropoietin Sales Market Share in Value by Region (2024-2029)
Table 47. Global Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2029)
Table 48. Global Short-acting Recombinant Human Erythropoietin Sales by Application: 2018 VS 2022 VS 2029 (US$ Million)
Table 49. Global Short-acting Recombinant Human Erythropoietin Sales by Application (2018-2024) & (K Units)
Table 50. Global Short-acting Recombinant Human Erythropoietin Sales Market Share in Volume by Application (2018-2024)
Table 51. Global Short-acting Recombinant Human Erythropoietin Sales by Application (2018-2024) & (US$ Million)
Table 52. Global Short-acting Recombinant Human Erythropoietin Sales Market Share in Value by Application (2018-2024)
Table 53. Global Short-acting Recombinant Human Erythropoietin Price by Application (2018-2024) & (US$/Unit)
Table 54. Global Short-acting Recombinant Human Erythropoietin Sales by Application (2024-2029) & (K Units)
Table 55. Global Short-acting Recombinant Human Erythropoietin Sales Market Share in Volume by Application (2024-2029)
Table 56. Global Short-acting Recombinant Human Erythropoietin Sales by Application (2024-2029) & (US$ Million)
Table 57. Global Short-acting Recombinant Human Erythropoietin Sales Market Share in Value by Application (2024-2029)
Table 58. Global Short-acting Recombinant Human Erythropoietin Price by Application (2024-2029) & (US$/Unit)
Table 59. North America Short-acting Recombinant Human Erythropoietin Sales by Application (2018-2024) (K Units)
Table 60. North America Short-acting Recombinant Human Erythropoietin Sales by Application (2018-2024) & (US$ Million)
Table 61. Europe Short-acting Recombinant Human Erythropoietin Sales by Application (2018-2024) (K Units)
Table 62. Europe Short-acting Recombinant Human Erythropoietin Sales by Application (2018-2024) & (US$ Million)
Table 63. Asia-Pacific Short-acting Recombinant Human Erythropoietin Sales by Application (2018-2024) (K Units)
Table 64. Asia-Pacific Short-acting Recombinant Human Erythropoietin Sales by Application (2018-2024) & (US$ Million)
Table 65. Latin America Short-acting Recombinant Human Erythropoietin Sales by Application (2018-2024) (K Units)
Table 66. Latin America Short-acting Recombinant Human Erythropoietin Sales by Application (2018-2024) & (US$ Million)
Table 67. Middle East and Africa Short-acting Recombinant Human Erythropoietin Sales by Application (2018-2024) (K Units)
Table 68. Middle East and Africa Short-acting Recombinant Human Erythropoietin Sales by Application (2018-2024) & (US$ Million)
Table 69. North America Short-acting Recombinant Human Erythropoietin Sales by Country (2018-2024) & (K Units)
Table 70. North America Short-acting Recombinant Human Erythropoietin Sales Market Share in Volume by Country (2018-2024)
Table 71. North America Short-acting Recombinant Human Erythropoietin Sales by Country (2018-2024) & (US$ Million)
Table 72. North America Short-acting Recombinant Human Erythropoietin Sales Market Share in Value by Country (2018-2024)
Table 73. North America Short-acting Recombinant Human Erythropoietin Sales by Country (2024-2029) & (K Units)
Table 74. North America Short-acting Recombinant Human Erythropoietin Sales Market Share in Volume by Country (2024-2029)
Table 75. North America Short-acting Recombinant Human Erythropoietin Sales by Country (2024-2029) & (US$ Million)
Table 76. North America Short-acting Recombinant Human Erythropoietin Sales Market Share in Value by Country (2024-2029)
Table 77. Europe Short-acting Recombinant Human Erythropoietin Sales by Country (2018-2024) & (K Units)
Table 78. Europe Short-acting Recombinant Human Erythropoietin Sales Market Share in Volume by Country (2018-2024)
Table 79. Europe Short-acting Recombinant Human Erythropoietin Sales by Country (2018-2024) & (US$ Million)
Table 80. Europe Short-acting Recombinant Human Erythropoietin Sales Market Share in Value by Country (2018-2024)
Table 81. Europe Short-acting Recombinant Human Erythropoietin Sales by Country (2024-2029) & (K Units)
Table 82. Europe Short-acting Recombinant Human Erythropoietin Sales Market Share in Volume by Country (2024-2029)
Table 83. Europe Short-acting Recombinant Human Erythropoietin Sales by Country (2024-2029) & (US$ Million)
Table 84. Europe Short-acting Recombinant Human Erythropoietin Sales Market Share in Value by Country (2024-2029)
Table 85. Asia-Pacific Short-acting Recombinant Human Erythropoietin Sales by Region (2018-2024) & (K Units)
Table 86. Asia-Pacific Short-acting Recombinant Human Erythropoietin Sales Market Share in Volume by Region (2018-2024)
Table 87. Asia-Pacific Short-acting Recombinant Human Erythropoietin Sales by Region (2018-2024) & (US$ Million)
Table 88. Asia-Pacific Short-acting Recombinant Human Erythropoietin Sales Market Share in Value by Region (2018-2024)
Table 89. Asia-Pacific Short-acting Recombinant Human Erythropoietin Sales by Region (2024-2029) & (K Units)
Table 90. Asia-Pacific Short-acting Recombinant Human Erythropoietin Sales Market Share in Volume by Region (2024-2029)
Table 91. Asia-Pacific Short-acting Recombinant Human Erythropoietin Sales by Region (2024-2029) & (US$ Million)
Table 92. Asia-Pacific Short-acting Recombinant Human Erythropoietin Sales Market Share in Value by Region (2024-2029)
Table 93. Latin America Short-acting Recombinant Human Erythropoietin Sales by Country (2018-2024) & (K Units)
Table 94. Latin America Short-acting Recombinant Human Erythropoietin Sales Market Share in Volume by Country (2018-2024)
Table 95. Latin America Short-acting Recombinant Human Erythropoietin Sales by Country (2018-2024) & (US$ Million)
Table 96. Latin America Short-acting Recombinant Human Erythropoietin Sales Market Share in Value by Country (2018-2024)
Table 97. Latin America Short-acting Recombinant Human Erythropoietin Sales by Country (2024-2029) & (K Units)
Table 98. Latin America Short-acting Recombinant Human Erythropoietin Sales Market Share in Volume by Country (2024-2029)
Table 99. Latin America Short-acting Recombinant Human Erythropoietin Sales by Country (2024-2029) & (US$ Million)
Table 100. Latin America Short-acting Recombinant Human Erythropoietin Sales Market Share in Value by Country (2024-2029)
Table 101. Middle East and Africa Short-acting Recombinant Human Erythropoietin Sales by Country (2018-2024) & (K Units)
Table 102. Middle East and Africa Short-acting Recombinant Human Erythropoietin Sales Market Share in Volume by Country (2018-2024)
Table 103. Middle East and Africa Short-acting Recombinant Human Erythropoietin Sales by Country (2018-2024) & (US$ Million)
Table 104. Middle East and Africa Short-acting Recombinant Human Erythropoietin Sales Market Share in Value by Country (2018-2024)
Table 105. Middle East and Africa Short-acting Recombinant Human Erythropoietin Sales by Country (2024-2029) & (K Units)
Table 106. Middle East and Africa Short-acting Recombinant Human Erythropoietin Sales Market Share in Volume by Country (2024-2029)
Table 107. Middle East and Africa Short-acting Recombinant Human Erythropoietin Sales by Country (2024-2029) & (US$ Million)
Table 108. Middle East and Africa Short-acting Recombinant Human Erythropoietin Sales Market Share in Value by Country (2024-2029)
Table 109. Amgen Company Information
Table 110. Amgen Introduction and Business Overview
Table 111. Amgen Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 112. Amgen Short-acting Recombinant Human Erythropoietin Product
Table 113. Amgen Recent Development
Table 114. Johnson & Johnson Company Information
Table 115. Johnson & Johnson Introduction and Business Overview
Table 116. Johnson & Johnson Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 117. Johnson & Johnson Short-acting Recombinant Human Erythropoietin Product
Table 118. Johnson & Johnson Recent Development
Table 119. Roche Company Information
Table 120. Roche Introduction and Business Overview
Table 121. Roche Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 122. Roche Short-acting Recombinant Human Erythropoietin Product
Table 123. Roche Recent Development
Table 124. Kyowa Kirin Company Information
Table 125. Kyowa Kirin Introduction and Business Overview
Table 126. Kyowa Kirin Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 127. Kyowa Kirin Short-acting Recombinant Human Erythropoietin Product
Table 128. Kyowa Kirin Recent Development
Table 129. LG Chem Company Information
Table 130. LG Chem Introduction and Business Overview
Table 131. LG Chem Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 132. LG Chem Short-acting Recombinant Human Erythropoietin Product
Table 133. LG Chem Recent Development
Table 134. Daewoong Pharmaceutical Company Information
Table 135. Daewoong Pharmaceutical Introduction and Business Overview
Table 136. Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 137. Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Product
Table 138. Daewoong Pharmaceutical Recent Development
Table 139. Wockhardt Company Information
Table 140. Wockhardt Introduction and Business Overview
Table 141. Wockhardt Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 142. Wockhardt Short-acting Recombinant Human Erythropoietin Product
Table 143. Wockhardt Recent Development
Table 144. CJ Healthcare Company Information
Table 145. CJ Healthcare Introduction and Business Overview
Table 146. CJ Healthcare Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 147. CJ Healthcare Short-acting Recombinant Human Erythropoietin Product
Table 148. CJ Healthcare Recent Development
Table 149. 3SBio Company Information
Table 150. 3SBio Introduction and Business Overview
Table 151. 3SBio Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 152. 3SBio Short-acting Recombinant Human Erythropoietin Product
Table 153. 3SBio Recent Development
Table 154. Kexing Biopharm Company Information
Table 155. Kexing Biopharm Introduction and Business Overview
Table 156. Kexing Biopharm Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 157. Kexing Biopharm Short-acting Recombinant Human Erythropoietin Product
Table 158. Kexing Biopharm Recent Development
Table 159. Harbin Pharmaceutical Group Company Information
Table 160. Harbin Pharmaceutical Group Introduction and Business Overview
Table 161. Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 162. Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Product
Table 163. Harbin Pharmaceutical Group Recent Development
Table 164. Beijing Four Rings Bio-Pharmaceutical Company Information
Table 165. Beijing Four Rings Bio-Pharmaceutical Introduction and Business Overview
Table 166. Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 167. Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Product
Table 168. Beijing Four Rings Bio-Pharmaceutical Recent Development
Table 169. Key Raw Materials Lists
Table 170. Raw Materials Key Suppliers Lists
Table 171. Short-acting Recombinant Human Erythropoietin Market Trends
Table 172. Short-acting Recombinant Human Erythropoietin Market Drivers
Table 173. Short-acting Recombinant Human Erythropoietin Market Challenges
Table 174. Short-acting Recombinant Human Erythropoietin Market Restraints
Table 175. Short-acting Recombinant Human Erythropoietin Distributors List
Table 176. Short-acting Recombinant Human Erythropoietin Downstream Customers
Table 177. Research Programs/Design for This Report
Table 178. Key Data Information from Secondary Sources
Table 179. Key Data Information from Primary Sources
List of Figures
Figure 1. Short-acting Recombinant Human Erythropoietin Product Picture
Figure 2. Global Short-acting Recombinant Human Erythropoietin Market Size, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Short-acting Recombinant Human Erythropoietin Market Size Status and Outlook (2018-2029) & (US$ Million)
Figure 4. Global Short-acting Recombinant Human Erythropoietin Sales Status and Outlook (2018-2029) & (K Units)
Figure 5. Product Picture of Epoetin-alfa
Figure 6. Global Epoetin-alfa Sales YoY Growth (2018-2029) & (K Units)
Figure 7. Product Picture of Epoetin-beta
Figure 8. Global Epoetin-beta Sales YoY Growth (2018-2029) & (K Units)
Figure 9. Product Picture of Darbepoetin-alfa
Figure 10. Global Darbepoetin-alfa Sales YoY Growth (2018-2029) & (K Units)
Figure 11. Product Picture of Others
Figure 12. Global Others Sales YoY Growth (2018-2029) & (K Units)
Figure 13. Global Short-acting Recombinant Human Erythropoietin Sales by Type (2018-2029) & (US$ Million)
Figure 14. Global Short-acting Recombinant Human Erythropoietin Sales Market Share by Type in 2022 & 2029
Figure 15. North America Short-acting Recombinant Human Erythropoietin Sales Market Share in Volume by Type in 2022
Figure 16. North America Short-acting Recombinant Human Erythropoietin Sales Market Share in Value by Type in 2022
Figure 17. Europe Short-acting Recombinant Human Erythropoietin Sales Market Share in Volume by Type in 2022
Figure 18. Europe Short-acting Recombinant Human Erythropoietin Sales Market Share in Value by Type in 2022
Figure 19. Asia-Pacific Short-acting Recombinant Human Erythropoietin Sales Market Share in Volume by Type in 2022
Figure 20. Asia-Pacific Short-acting Recombinant Human Erythropoietin Sales Market Share in Value by Type in 2022
Figure 21. Latin America Short-acting Recombinant Human Erythropoietin Sales Market Share in Volume by Type in 2022
Figure 22. Latin America Short-acting Recombinant Human Erythropoietin Sales Market Share in Value by Type in 2022
Figure 23. Middle East and Africa Short-acting Recombinant Human Erythropoietin Sales Market Share in Volume by Type in 2022
Figure 24. Middle East and Africa Short-acting Recombinant Human Erythropoietin Sales Market Share in Value by Type in 2022
Figure 25. The 5 and 10 Largest Manufacturers in the World: Market Share by Short-acting Recombinant Human Erythropoietin Sales in 2022
Figure 26. The 5 and 10 Largest Manufacturers in the World: Market Share by Short-acting Recombinant Human Erythropoietin Revenue in 2022
Figure 27. Short-acting Recombinant Human Erythropoietin Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 28. Product Picture of Anemia
Figure 29. Global Anemia Sales YoY Growth (2018-2029) & (K Units)
Figure 30. Product Picture of Kidney Disorders
Figure 31. Global Kidney Disorders Sales YoY Growth (2018-2029) & (K Units)
Figure 32. Product Picture of Others
Figure 33. Global Others Sales YoY Growth (2018-2029) & (K Units)
Figure 34. Global Short-acting Recombinant Human Erythropoietin Sales by Application (2018-2029) & (US$ Million)
Figure 35. Global Short-acting Recombinant Human Erythropoietin Sales Market Share by Application in 2022 & 2029
Figure 36. North America Short-acting Recombinant Human Erythropoietin Sales Market Share in Volume by Application in 2022
Figure 37. North America Short-acting Recombinant Human Erythropoietin Sales Market Share in Value by Application in 2022
Figure 38. Europe Short-acting Recombinant Human Erythropoietin Sales Market Share in Volume by Application in 2022
Figure 39. Europe Short-acting Recombinant Human Erythropoietin Sales Market Share in Value by Application in 2022
Figure 40. Asia-Pacific Short-acting Recombinant Human Erythropoietin Sales Market Share in Volume by Application in 2022
Figure 41. Asia-Pacific Short-acting Recombinant Human Erythropoietin Sales Market Share in Value by Application in 2022
Figure 42. Latin America Short-acting Recombinant Human Erythropoietin Sales Market Share in Volume by Application in 2022
Figure 43. Latin America Short-acting Recombinant Human Erythropoietin Sales Market Share in Value by Application in 2022
Figure 44. Middle East and Africa Short-acting Recombinant Human Erythropoietin Sales Market Share in Value by Application in 2022
Figure 45. Key Raw Materials Price
Figure 46. Short-acting Recombinant Human Erythropoietin Manufacturing Cost Structure
Figure 47. Short-acting Recombinant Human Erythropoietin Industrial Chain Analysis
Figure 48. Channels of Distribution
Figure 49. Distributors Profiles
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries